7. Fixed pharmaceutical composition according to either claim 1 or claim 5, wherein the perindopril is in the form of perindopril tert-butylamine or perindopril arginine and more preferably in the form of perindopril arginine.

8. Fixed pharmaceutical composition according to any one of claims 1 to 7, wherein:

- the doses of bisoprolol are 1.05 mg and 8.50 mg, expressed in terms of bisoprolol base,

or between 1.25 and 10 mg, expressed in terms of bisoprolol fumarate, and

- the doses of perindopril are 1.65 and 6.80 mg, expressed in terms of perindopril base, or

between 2.5 and 10 mg, expressed in terms of perindopril arginine.

9. Fixed pharmaceutical composition according to any one of claims 1 to 8, wherein the doses

of bisoprolol fumarate are 2.5 mg, 5 mg and 10 mg and the doses of perindopril arginine

are 2.5 mg, 5 mg and 10 mg.

10. Use of fixed pharmaceutical compositions according to any one of claims 1 to 9 for manufacture of a medicament for the treatment or prevention of cardiovascular diseases.

11. Use of fixed pharmaceutical compositions according to claim 10, characterised in that the cardiovascular diseases are chosen from arterial hypertension, stable coronary artery disease and chronic heart failure.